34 results about "Cannabinoid Receptor Agonists" patented technology

This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.

Compositions and methods for treating noninflammatory pain, including but not limited to, neuropathic pain by using peroxisome proliferator activated receptor a (PPARa) agonists to treat a subject having such pain are described. The agonists may be used with additional therapeutic agents such as an inhibitor of fatty acid amide hydrolase or a cannabinoid CB1 or CB2 cannabinoid receptor agonist.

An imine compound represented by the formula (I) (wherein A represents a heterocyclic group; R<1>, R<2>, and R<3> each represents hydrogen, halogeno, C1-10 alkyl optionally substituted by haloaryl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-10 alkoxy, etc.; R<4> represents optionally substituted C1-10 alkyl, C2-6 alkenyl, or aryl; R<5> represents hydrogen, C1-10 alkoxy, C1-6 haloalkyl, optionally substituted C1-10 alkyl or C2-6 alkenyl, optionally substituted aryl or heterocyclic group, etc.; and W represents -CO-, -CO-CO-, -CO-NH-, -CS-NH-, or -SO2-) or a cannabinoid receptor agonist containing the compound as an active ingredient. The imine compound has agonistic activity against a cannabinoid receptor and is useful as a therapeutic or preventive agent for pains and autoimmune diseases.

The administration of cannabinoid receptor agonists for inhibition of transient lower esophageal sphincter relaxations, gastroesophageal reflux disease and regurgitation is disclosed.

Described herein are methods of improving immune homeostasis in the gut of a subject suffering from an autoimmune disease characterized by inflammation of the gut by administering, e.g., orally administering, to the subject an effective amount of a cannabinoid receptor agonist to improve immune homeostasis in the gut of the subject. Exemplary cannabinoid receptor ligands include Anandamide. The methods are particularly useful to treat gut inflammation associated with diabetes mellitus Type I.

The present invention relates to a composition comprising: i) at least one strain of a Lactobacillus sp and/or a metabolite thereof; and ii) a cannabinoid receptor agonist and/or a opioid receptor agonist. In addition, the present invention relates to methods using and uses of such a composition.

The present invention relates to the use of a cannabinoid receptor agonist for use in induction of hypothermia in a human being for the prophylaxis and treatment of ischemia.

Miltefosine is utilized to enhance immune response to vaccination, for example an influenza and/or coronavirus vaccination. The inventive subject matter also provides compositions and methods for enhancing viral yield in cultured cells, by application of a cannabinoid receptor agonist (such as methanandamide) to such cells. Such enhanced viral yield can be used to enhance virus production for purposes of vaccine formulation and/or to improve sensitivity of cell-based virus assays.

The invention relates to the field of medicine for treating newborn cerebral hemorrhage, in particular to application of II type cannabinoid receptor stimulant in preparation of medicine for treating newborn cerebral hemorrhage. The application of the II type cannabinoid receptor stimulant in preparation of medicine for promoting nerve regeneration, neural precursor cell differentiation and neural stem cell proliferation after treating newborn cerebral hemorrhage is provided. It is found through tests that the II type cannabinoid receptor stimulant has the effects of promoting newborn nerve regeneration, neural precursor cell differentiation and neural stem cell proliferation; in addition, GMH-induced hydrocephalus can be remarkably reduced. In addition, the II type cannabinoid receptor stimulant is used in cooperation with minocyline which can remarkably increase transmittance of the blood brain barrier of the II type cannabinoid receptor stimulant and add the anti-inflammation effect treatment effect.

An inhibitor for inflammatory cellular infiltration in the respiratory tract, inhibitor for hyperirritability in the respiratory tract, muciparous inhibitor, or bronchodilator which contains as an active ingredient a compound selected from the group of compounds represented by the formulae (I) and (II).

The present invention relates to the use of a cannabinoid receptor agonist for use in induction of hypothermia in a human being for the prophylaxis and treatment of ischemia.

Peripherally acting cannabinoid agonist compounds, pharmaceutical compositions, and methods of using them are presented.

Provided herein are formulations for treating affective mood disorders. The formulations comprise one or more than one CB receptor agonist and one or more than one serine hydrolase enzyme inhibitor.

The invention provides a preparation method and application of oligodendroglia cells. The provided regimen reproduces the major step of oligodendrocyte differentiation in a time that is significantly shorter than 75-95 days required for previous regimens. The NSC differentiation is induced through a cannabinoid receptor agonist WIN55212-2, and the induction of OLIG2 + OPC is promoted. The WIN-derived OLIG2 + progenitor cells are differentiated into PDGFR alpha + OPCs, have high mobility, and can be further differentiated into mature OL with strong myelination ability. When the WIN-derived OPC is transplanted to a diseased region, the athletic ability of a spinal cord injury (SCI) mouse is significantly improved from the second week after transplantation. Immunostaining results show that the WIN-derived OPC can be differentiated into mature OL, so that damaged axons are myelinated. The method and the product disclosed by the invention are widely applied to the field of cell therapy, and particularly have a remarkable treatment effect on spinal cord injury.

The present application describes a method of treating conditions treatable with a CB₂ cannabinoid receptor agonist with reduced CB₁-mediated side effects using a combination therapy comprising a CB₂ agonist and a CB₁ ligand, which can be a CB₁ antagonist or a CB₁ inverse agonist.

The invention belongs to the field of biological medicines, and relates to a new application of a cannabinoid receptor drug, in particular to an application of a cannabinoid receptor type 1 (CB1R) antagonist and a cannabinoid receptor type 2 (CB2R) agonist in preparation of a drug for treating myocardial cell necrotic apoptosis. The invention also provides a corresponding kit. Quetiapine is a common atypical antipsychotic and is used for treating schizophrenia, bipolar affective disorder, severe depression and other mental disorders. Experiments prove that quetiapine promotes inflammatory infiltration and fibrosis reconstruction of myocardial cells; quetiapine has the effect of promoting RIP3 and MLKL and activates a myocardial cell necrotic apoptosis pathway, and the cannabinoid receptortype 1 (CB1R) antagonist and the cannabinoid receptor type 2 (CB2R) agonist can significantly inhibit the necrotic apoptosis pathway, so the cannabinoid receptor type 1 (CB1R) antagonist and the cannabinoid receptor type 2 (CB2R) agonist are used for treating quetiapine cardiotoxicity. The invention provides a novel application of the cannabinoid receptor type 1 (CB1R) antagonist and the cannabinoid receptor type 2 (CB2R) agonist, and provides novel reference data for development of myocardial cytotoxicity treatment drugs.

The invention relates to the field of cerebral hemorrhage drugs, in particular to application of type-II cannabinoid receptor agonist in the preparation of drugs for inhibiting microglial cell proliferation and treating hypertensive cerebral hemorrhage after the treatment of hypertensive cerebral hemorrhage.In-vivo experiments show that the type-II cannabinoid receptor agonist is capable of inhibiting microglial cell proliferation and activation after cerebral hemorrhage, inhibiting perihematomal neurogenic inflammations and improving secondary brain injury caused by cerebral hemorrhage; in addition, in the use with the type-II cannabinoid receptor agonist, minocycline is capable of significantly increasing blood brain barrier penetration rate of the type-II cannabinoid receptor agonist and improving anti-inflammatory therapeutic effect.

The invention relates to the field of cerebral hemorrhage drugs, in particular to the application of type II cannabinoid receptor agonists in the preparation of drugs for the recovery of neurological function and brain atrophy after hypertensive cerebral hemorrhage. The invention provides the application of a type II cannabinoid receptor agonist in the preparation of a drug for the recovery of neurological function and cerebral edema after hypertensive cerebral hemorrhage. The present invention finds through in vivo experiments that the type II cannabinoid receptor agonist can reduce the degree of brain tissue edema induced by autologous blood and prevent brain atrophy; the use of the drug after hypertensive cerebral hemorrhage can significantly improve neurological function recovery. In addition, the type II cannabinoid receptor agonist is used in combination with minocycline, and the minocycline can significantly increase the blood-brain barrier penetration rate of the type II cannabinoid receptor agonist, and increase the therapeutic effect of anti-inflammatory effect.

Provided herein are formulations for treating affective mood disorders. The formulations comprise one or more than one CB receptor agonist and one or more than one serine hydrolase enzyme inhibitor.

The invention relates to discovery and application of a cannabinoid receptor new agonist and three new antagonists. The agonist is Kfb77, and the antagonists are Kfb28, Kfb68 and Kga1. In-vitro cell experiments show that the compound Kfb77 has an excitation effect on a cannabinoid type I receptor (CB1), the compound Kga1 has an antagonism effect on CB1, the compound Kfb28 has an antagonism effecton a cannabinoid type II receptor (CB2), and the compound Kfb68 has an antagonism effect on CB1 and CB2. Accordingly, the new natural agonist and antagonists for the CB1 and the CB2 provided by the invention provide candidate compounds for research and development of drugs for treating neurodegenerative diseases such as psychotic diseases, obesity/metabolic disorder related diseases, immune systemregulation and multiple sclerosis.